Therapeutic combination of a panher/vegfr2 kinase inhibitor and a platinum compound
AssigneeBristol-Meyers Squibb Company
InventorsTai W. Wong, Jean Soria, Guido Kroemer
Life of this patent
Estimating the term…
Abstract
This invention relates to a synergistic therapeutic combination of anti-cancer compounds which comprises a) a panHER/VEGFR2 kinase inhibitor, and b) a platinum compound, and optionally at least one pharmaceutically acceptable carrier for simultaneous, separate or sequential use. The invention also relates to treating certain cancers utilizing the combination of the invention.
Claims15
A synergistic pharmaceutical combination of anti-cancer compounds which comprises administering to a mammal a dosage unit of
- a) a panHER/VEGFR2 kinase inhibitor, and a dosage unit of
- b) a platinum compound,
- in which the active ingredients are present in each case in free form or as a pharmaceutically acceptable salt or stereoisomer thereof.
A method for treating cancer which comprises administering to a mammal a combination therapy comprising a dosage unit of
- a) a panHER/VEGFR2 kinase inhibitor, and a dosage unit of
- b) a platinum compound,
- in which the active ingredients are present in each case in free form or as a pharmaceutically acceptable salt or stereoisomer thereof,
- wherein the combination therapy will provide a greater anti-cancer effect than the effect obtainable with either the dosage unit of Compound (1) or the platinum compound alone.
Dependencies are inferred from the claim text.